BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer. 2008;98:1161-1165. [PMID: 18349849 DOI: 10.1038/sj.bjc.6604282] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol. 2015;21; 5607-5621. [PMID: 25987786 DOI: 10.3748/wjg.v21.i18.5607] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
2 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 22.5] [Reference Citation Analysis]
3 Yoon H, Kim J, Kim K, Lee I, Ko G, Song H, Gwon D. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clinical Radiology 2010;65:271-7. [DOI: 10.1016/j.crad.2010.01.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
4 Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ, Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol. 2015;21:4627-4634. [PMID: 25914472 DOI: 10.3748/wjg.v21.i15.4627] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
5 Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer 2016;5:175-89. [PMID: 27493893 DOI: 10.1159/000367765] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
6 Mumtaz K, Patel N, Modi RM, Patel V, Hinton A, Hanje J, Black SM, Krishna S. Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey. Hepatobiliary Pancreat Dis Int 2017;16:624-30. [PMID: 29291782 DOI: 10.1016/S1499-3872(17)60077-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011;81:39-44. [PMID: 21912196 DOI: 10.1159/000331411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
10 Liu G, Xie C, Sun F, Xu X, Yang Y, Zhang T, Deng Y, Wang D, Huang Z, Yang L, Huang S, Wang Q, Liu G, Zhong D, Miao X. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genetics and Cytogenetics 2010;197:54-9. [DOI: 10.1016/j.cancergencyto.2009.08.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
11 Henry JC, Malhotra L, Khabiri H, Guy G, Michaels A, Hanje J, Azevedo M, Bloomston M, Schmidt CR. Best radiological response to trans-arterial chemoembolization for hepatocellular carcinoma does not imply better outcomes. HPB (Oxford) 2013;15:196-202. [PMID: 23374360 DOI: 10.1111/j.1477-2574.2012.00529.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 258] [Article Influence: 45.7] [Reference Citation Analysis]
13 Pang Q, Qu K, Zhang JY, Song SD, Liu SS, Tai MH, Liu HC, Liu C. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e1431. [PMID: 26376382 DOI: 10.1097/MD.0000000000001431] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
14 Li M, Bai J, Wang S, Zhai Y, Zhang S, Li C, Du J, Zhang Y. Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study. BMC Cancer 2020;20:988. [PMID: 33046024 DOI: 10.1186/s12885-020-07497-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
16 Gupta P, Kalra N, Keshava SN, Chaluvashetty SB, Mukund A, Roy-choudhury SH, Baijal SS, Khandelwal A, Ananthashayana VH, R. SN, Kulkarni S, Shetty NS, Gupta A, Gupta S. Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I. Journal of Clinical Interventional Radiology ISVIR 2020;4:098-106. [DOI: 10.1055/s-0040-1715774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
17 Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
18 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
19 Zeng Q, Qiu J, Hong J, Li Y, Li S, Zou R, Huang P, Li B, Zheng Y, Lao X, Yuan Y. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis: . European Journal of Gastroenterology & Hepatology 2012;24:575-82. [DOI: 10.1097/meg.0b013e328351046a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Cai ZQ, Si SB, Chen C, Zhao Y, Ma YY, Wang L, Geng ZM. Analysis of prognostic factors for survival after hepatectomy for hepatocellular carcinoma based on a Bayesian network. PLoS One. 2015;10:e0120805. [PMID: 25826337 DOI: 10.1371/journal.pone.0120805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
21 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
22 Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130:2747-2760. [PMID: 22261860 DOI: 10.1002/ijc.27441] [Cited by in Crossref: 202] [Cited by in F6Publishing: 186] [Article Influence: 22.4] [Reference Citation Analysis]
23 Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, Springer F, Claussen CD, Brechtel K. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. Eur J Gastroenterol Hepatol 2012;24:1325-32. [PMID: 22872074 DOI: 10.1097/MEG.0b013e32835724bc] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
24 Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47:421-426. [PMID: 22048256 DOI: 10.1007/s00535-011-0492-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sangro B, D'avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:1057-73. [DOI: 10.1517/14656566.2011.545346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
26 . Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer 2015;4:85-95. [PMID: 26020031 DOI: 10.1159/000367730] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
27 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. Hepatol Res. 2015;Aug 29; Epub ahead of print. [PMID: 26331402 DOI: 10.1111/hepr.12583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XH. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571-584. [PMID: 23153532 DOI: 10.1016/j.ccr.2012.08.013] [Cited by in Crossref: 603] [Cited by in F6Publishing: 573] [Article Influence: 75.4] [Reference Citation Analysis]
30 Nouso K, Kariyama K, Nakamura S, Oonishi A, Wakuta A, Oyama A, Ako S, Dohi C, Wada N, Morimoto Y, Takeuchi Y, Kuwaki K, Onishi H, Ikeda F, Shiraha H, Takaki A, Okada H. Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma: Application of radiofrequency ablation. Journal of Gastroenterology and Hepatology 2017;32:695-700. [DOI: 10.1111/jgh.13586] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
31 Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Goo DE, Park SY. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Gut Liver 2017;11:409-16. [PMID: 28208001 DOI: 10.5009/gnl16001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
32 Tao Y, Li Y, Liu X, Deng Q, Yu Y, Yang Z. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:2695-2709. [PMID: 30147368 DOI: 10.2147/cmar.s167560] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
33 Kudo M. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer 2018;7:134-47. [PMID: 29888204 DOI: 10.1159/000484619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]